Effects of pomegranate peel dry extract supplementation on non-alcoholic fatty liver

Effects of pomegranate peel dry extract supplementation on lipid profile, inflammatory and oxidative stress factors and nutritional status in patients with non-alcoholic fatty liver: A randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210726051988N1

Enrollment

Registered

2021-09-14

Start date

2021-10-07

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver- hepatic steatosis and fibrosis- pomegranate peel. Fatty (Chang of) liver, not elsewhere classified, Nonalcoholic fatty liver disease

Interventions

Intervention 1: In the intervention group, in addition to lifestyle interventions (diet therapy + physical activity), supplementation of dry extract of pomegranate peel with a dose of 1500 mg is perfo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 18-60 years old Detection of hepatic steatosis by two-dimensional elastography device Filling out the informed consent form by the patient

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Morbid obesity (BMI > 40) Alcohol consumption history (more than 20 grams per day for women and more than 30 grams per day for men), Having any type of immunodeficiency disorder, including: autoimmune disorders, cancer, human immunodeficiency virus (HIV) Hepatic or renal insufficiency, other liver diseases such as hepatitis, alcoholic fatty liver consumption of hepatotoxic drugs such as sodium valproate History of food allergy to pomegranate and herbal supplements History of bariatric surgery

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis and fibrosis. Timepoint: before and at the end of the study. Method of measurement: Two-dimensional elastography device.	—

Secondary

Measure	Time frame
Measurement of anthropometric indices (height, weight, body mass index). Timepoint: Before, in the middle and at the end of the study. Method of measurement: Scales with an accuracy of 100 grams, meters,.;Measurement of body composition (percentage of adipose and lean tissue) by BIA device. Timepoint: Before, in the middle and at the end of the study. Method of measurement: BIA.;Measurement of serum concentrations of oxidative stress indicators including malondialdehyde, superoxide dismutase, glutathione peroxidase,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Evaluation of IPAQ physical activity questionnaire and three-day food recall. Timepoint: Before, in the middle and at the end of the study. Method of measurement: statistical methods.;Measurement of serum concentrations of lipid profiles including TC, HDL-C, LDL-C and TG,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of fasting blood glucose and insulin,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of hepatic profiles including ALT, ALP and AST,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of inflammatory markers including interleukin 6 and reactive protein C. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.	—

Measure

Time frame

Measurement of anthropometric indices (height, weight, body mass index). Timepoint: Before, in the middle and at the end of the study. Method of measurement: Scales with an accuracy of 100 grams, meters,.;Measurement of body composition (percentage of adipose and lean tissue) by BIA device. Timepoint: Before, in the middle and at the end of the study. Method of measurement: BIA.;Measurement of serum concentrations of oxidative stress indicators including malondialdehyde, superoxide dismutase, glutathione peroxidase,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Evaluation of IPAQ physical activity questionnaire and three-day food recall. Timepoint: Before, in the middle and at the end of the study. Method of measurement: statistical methods.;Measurement of serum concentrations of lipid profiles including TC, HDL-C, LDL-C and TG,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of fasting blood glucose and insulin,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of hepatic profiles including ALT, ALP and AST,. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of inflammatory markers including interleukin 6 and reactive protein C. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHanieh Barghchi

Mashhad University of Medical Sciences

barghchihn981@mums.ac.ir+98 51 3800 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026